Clinical management of diabetic nephropathy

Diabetes, Obesity and Metabolism

Volumn 1, Issue 6, 1999, Pages 307-315

  McLaughlin, Kevin ^a   Jardine, Alan G ^a,b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN RESTRICTION; REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIET, PROTEIN-RESTRICTED; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 0033224555     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.1999.00041.x     Document Type: Review

References (56)

1. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213-219.
2. Ruggenenti P, Remuzzi G. Nephropathy of type 2 diabetes mellitus. J Am Soc Nephrol 1998; 9: 2157-2169.
3. Rossing P. Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. Diabetic Med 1998; 15: 900-919.
4. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1-28.
5. Cohen MP, Ziyadeh FN. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol 1996; 7: 183-190.
6. Soulis T, Cooper M, Vranes D, Bucala R, Jerums G. The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 1996; 50: 627-634.
7. Goldfarb S, Ziyadeh FN, Kern EF, Simmons DA. Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes 1991; 40: 465-471.
8. Koya D, King GI. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
9. Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-731.
10. Gilbert RE, Cox A, Wu LL et al. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effect of angiotensin converting enzyme inhibition. Diabetes 1998; 47: 414-422.
11. Yokoyama H, Deckert T. Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis. Diabetic Med 1996; 13: 313-320.
12. Hoffman BB, Sharma K, Zhu Y, Zihadeh FN. Transcriptional activation of transforming growth factor beta-1 in mesangial cell culture by high glucose concentration. Kidney Int 1998; 54: 1107-1116.
13. Muntoni S, Fonte MT, Stoduto S et al. Incidence of insulin-dependent diabetes mellitus among Sardinian-heritage children born in Lazio region, Italy. Lancet 1997; 349: 160-162.
14. Davies TL, Kawaguchi Y, Bennett ST et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994; 371: 130-136.
15. Krowlewski AS, Canessa M, Warram JH et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. New Engl J Med 1988; 318: 140-145.
16. Chowdhury TA, Kumar S, Barnett AH, Bain SC. Nephropathy in type 1 diabetes: the role of genetic factors. Diabetic Med 1995; 12: 1059-1067.
17. Jardine AG, Padmanabhan N, Connell JMC. Angiotensin converting enzyme gene polymorphisms and renal disease. Curr Op Nephrol Hypertens 1998; 7: 259-264.
18. Kunz R, Bork JP, Fritsche L, Ringel J, Sharma AM. Association between the ACE I/D polymorphisms and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol 1998; 9; 1653-1663.
19. Fujisawa T, Ikegawa H, Kawaguchi Y et al. Meta analysis of the association of the I/D polymorphisms of the ACE gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41: 47-53.
20. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. New Engl J Med 1993; 329: 1456-1462.
21. Nielsen FS, Rossing P, Gall MA, Smidt UM, Parving HH. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46: 1182-11888.
22. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-343.
23. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
24. Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med 1993; 118: 577-581.
25. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Int Med 1996; 156: 286-289.
26. Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomised control trial. Ann Int Med 1998; 128: 982-988.
27. Tatti P, Pahor M, Byington RP et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 655-657.
28. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 334: 645-652.
29. Bakris G. Combination therapy for hypertension and renal disease in diabetics as compared to non-diabetics. In: Mogensen C.E. eds. The Kidney and Hypertension in Diabetes Mellitus, 3rd edn. Norwell, MA: Kluwer Academic Publishers, 1997: 561-568.
30. McLaughlin K, Jardine AG. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: either or both for primary renal disease? Nephrol Dial Trans 1999; 14: 25-28.
31. Hansson L, Zanchetti A, Carruthers SG et al. for the HOT study group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
33. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
34. Joint National Committee on Prevention, Detection, Evaluation, Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Int Med 1997; 157: 2413-2445.
35. Chase HP, Jackson WE, Hoops SL, Cockerham RS, Archer PG, O'Brien D. Glucose control and renal and retinal complications ofsulin-dependent diabetes. J Am Med Assoc 1989; 261: 1155-1160.
36. The Diabetes Control, Complications (DCCT) Research Group. Effect offensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 7: 1703-1720.
37. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
38. Anonymous. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Contrological and Complications Trial. Diabetes 1996; 45: 1289-1298.
39. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. New Engl J Med 1998; 339: 69-75.
40. Smets YFC, Westendorp RGJ, vad der Fiji JW et al. Effect of simultaneous pancreas-kidney transplant on mortality of patients with type-1 diabetes mellitis and end-stage renal failure. Lancet 1999; 353: 1915-1919.
41. Tyden G, Bolinder J, Solders G, Brattstrom C, Tibell A, Groth C-G. Improved survival in patients with IDDM and end stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation. Transplantation 1999; 67: 645-648.
42. Stratta RS. Impact of pancreas transplantation on the complications of diabetes. Curr Op Organ Transplant 1998; 3: 258-273.
43. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal disease: a meta-analysis. Ann Int Med 1996; 124: 627-632.
44. Klahr S, Levey AS, Beck GJ et al. The effect of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. New Engl J Med 1994; 330: 877-884.
45. Hansen HP, Christensen PK, Tauber-Lassen E, Klansen A, Jensen BR, Parving HH. Low protein diet and kidney function in insulin-dependent diabetic patients with diabetic nephropathy. Kidney Int 1999; 55: 621-628.
46. Tonnolo G, Ciccarese M, Brizzi P et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997; 20: 1891-1894.
47. Mulec H, Johnson SA, Wiklund O, Bjorck S. Cholesterol a renal risk factor in diabetic nephropathy. Am J Kidney Dis 1993; 22: 196-201.
48. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995; 47: 907-910.
49. Kasiske BL, Garris WJ, Kean WF. Pharmacological treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circulation Res 1988; 62: 367-374.
50. Yoshimura A, Inui K, Nemoto T et al. Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 1998; 9: 2027-2039.
51. Lam KSL, Cheng IKP, Janus ED, Pang RWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-609.
52. American Diabetes Association. Position Statement: management of dyslipidaemia in adults with diabetes. Diabetes Care 1998; 21: 179-182.
53. Sacks FM, Pfeffer MA, Lemuel AM et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996; 335: 1001-1009.
54. Scandanavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383-1389.
55. Chase HP, Garg SK, Marshall G et al. Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. J Am Med Assoc 1991; 265: 614-617.
56. Biesenbach G, Grafinger P, Janko O, Zazgornik J. Influence of cigarette smoking on the progression of clinical diabetic nephropathy in type 2 diabetic patients. Clin Nephrol 1997; 48: 146-150.